EUVIMEDEUVIMED entdecken
Open Access

Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure

Steven Sun, Mina Nikanjam, Mark Mirochnick, Kathleen M Powis, Ahizechukwu C Eke, Alice Stek, Priyanka Arora, Tim R Cressey, Kristina M Brooks, Brookie M Best, Edmund V Capparelli, Jeremiah D Momper

The Journal of Clinical Pharmacology · 2026-01 · 66 (1)

DOI: 10.1002/jcph.70134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 17.12.2025. Verfasst von Steven Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San, Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 4 or More Rings, Postpartum Period, HIV Infections, Models, Biological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bictegravir is an integrase strand transfer inhibitor available in fixed‐dose combination with emtricitabine and tenofovir alafenamide for HIV treatment. The objectives of this study were to develop a population pharmacokinetic model for bictegravir during pregnancy and postpartum, identify main drivers of between‐subject variability, and evaluate the role of adherence patterns in maintaining therapeutic exposure. Intensive bictegravir concentration–time data were used from IMPAACT 2026, a pharmacokinetic study of selected antiretroviral drugs during pregnancy and postpartum. Five hundred and eight bictegravir plasma concentrations from 27 participants during the second and third trimesters of pregnancy and postpartum were utilized for model development. A one‐compartment structural model best described bictegravir PK. Pregnancy increased bictegravir apparent clearance (CL/F) by 61% compared to postpartum, while Black/African American race was associated with a 32% increase in apparent volume of distribution (Vd/F). Plasma albumin concentrations were associated with a 43% decrease in CL/F and body weight was associated with a 120% increase in Vd/F over the range of observed values. Monte Carlo simulations predicted median (90% prediction interval) pre‐dose bictegravir concentrations of 920 ng/mL (265–2081) during the third trimester and 3399 ng/mL (1423–6391) postpartum, exceeding the protein‐adjusted 95% effective concentration (162 ng/mL). Adherence simulations predicted a single missed dose at steady‐state during the third trimester results in 43.7% of virtual subjects with concentrations below pharmacodynamic target, while two consecutive missed doses result in 90.4% with concentrations below target. These results show that while standard bictegravir dosing is effective during pregnancy, consistent adherence is critical to maintain effective therapeutic exposures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 4 or More RingsPostpartum PeriodHIV InfectionsModels, BiologicalMedication AdherenceAnti-HIV AgentsHumansFemalePregnancyAdultPyridonesYoung AdultPiperazinesPyrimidinesMonte Carlo MethodPregnancy Complications, InfectiousAmidesHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

HIVbictegravirpopulation pharmacokineticspregnancy

Substanzen

bictegravirHeterocyclic Compounds, 4 or More RingsPyridonesAnti-HIV AgentsPiperazinesPyrimidinesAmidesHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San, Diego, La Jolla, CA, USA.
  • Division of Hematology-Oncology, University of California San Diego, La Jolla, CA, USA.
  • Department of Pediatrics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
  • Boston Medical Center, Boston, MA, USA.
  • Massachusetts General Hospital, Boston, MA, USA.
  • Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Sun, S., Nikanjam, M., Mirochnick, M., Powis, K. M., Eke, A. C., Stek, A., Arora, P., Cressey, T. R., Brooks, K. M., Best, B. M., Capparelli, E. V., & Momper, J. D. (2026). Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. The Journal of Clinical Pharmacology, 66(1). https://doi.org/10.1002/jcph.70134

Vancouver

Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, et al. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. The Journal of Clinical Pharmacology. 2026;66(1). doi:10.1002/jcph.70134

BibTeX
@article{Sun2026,
  author = {Sun, Steven and Nikanjam, Mina and Mirochnick, Mark and Powis, Kathleen M and Eke, Ahizechukwu C and Stek, Alice and Arora, Priyanka and Cressey, Tim R and Brooks, Kristina M and Best, Brookie M and Capparelli, Edmund V and Momper, Jeremiah D},
  title = {Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {1},
  doi = {10.1002/jcph.70134}
}
Kostenlos starten →